



Resolution n°9-2023-e

Additional ACT-A investments to accelerate and expand Unitaid's support for the development and introduction of molecular diagnostics

Acknowledging the need to sustain and build on the achievements of Unitaid and its partners within the ACT-A Diagnostics Pillar, including with respect to the development and introduction of molecular diagnostics;

Recalling Executive Board Resolution R16-2022-e, in which the Board approved the commitment of up to USD 15,9000,000 for the project entitled "DRIVEDX4TB: Accelerating Tools to Drive Tuberculosis Detection" (the "Project") to be implemented by FIND for a four-year period; and

Noting the opportunity to accelerate and expand this Project to build on Unitaid's ACT-A investments and support the development and commercialization in LMICs of a new class of molecular diagnostic platforms, within the current timeframe of the Project;

The Executive Board acknowledges the recommendations of the Secretariat and the Proposal Review Committee, and authorises the Executive Director to commit additional ACT-A funding of up to USD 6,000,000 (six million dollars) to FIND for the Project. This additional funding is conditional upon signature of formal amendment to the legal agreement for the Project.

The Board also notes the need to reinforce the additional investment in the Project by ensuring market preparation for the successful country introduction in LMICs of these molecular diagnostic platforms. The Board therefore authorizes the Executive Director to commit up to a further USD 3,000,000 (three million dollars) of ACT-A funding for the implementation of complementary activities aligned with these objectives. Proposals and implementers shall be selected for these purposes in accordance with the processes adopted in Board Resolution EB35/2020/4 and the timeframe for implementation shall also be aligned with the current timeframe of the Project.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 20 June 2023